Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system.
Our most clinically advanced product candidates are derived from our proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.
We currently have three PharmacoSurgery programs in clinical development. Our lead PharmacoSurgery drug product candidate, Omidria™ (OMS302) for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency.
In addition to our PharmacoSurgery platform, we have leveraged our expertise in inflammation, coagulopathies and the central nervous system to build a deep and diverse pipeline of preclinical programs targeting large markets. We have retained all manufacturing, marketing and distribution rights for each of our product candidates and programs.